Catinazzo Thomas sold $331K of RLAY
Catinazzo Thomas (Chief Financial Officer) sold 17,717 shares of Relay Therapeutics, Inc. (RLAY) at $18.69 ($0.33M total) on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling size, price, and post-transaction holdings, but does not include new operational or financial guidance.
Market read
Insider selling under a 10b5-1 plan is usually a low-signal event, more relevant for sentiment than fundamentals.
What to watch
Traders may overreact to insider sales; the key nuance here is the 10b5-1 pre-arranged nature, which often correlates with scheduled selling rather than new information.
Background
The article is a SEC Form 4 insider transaction report for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares on 2026-07-06 at $18.6900, per a filed Form 4.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a primary-source Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.
Market effects
No sector-level implications; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderThomas Catinazzo
Chief Financial Officer who executed the reported sale.
